Recordati Industria Chimica e Farmaceutica SPA (IT:REC) has released an update. Recordati Industria Chimica e Farmaceutica SPA reported strong ...

La Corte also said Recordati would unveil its 2025 outlook in February, along with preliminary 2024 results, taking into account its recent acquisition from Sanofi (SASY.PA), opens new tab of the ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

(RTTNews) - Sanofi announced that Beyfortus (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration ...

New drug Enjaymo recorded sales of €28 million in the quarter compared with €26 million in the previous quarter. Sanofi has sold global rights to Enjaymo to Recordati. The transaction is ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo Meanwhile, Sanofi saw revenues for its consumer health arm, Opella, grow 7.9%. Earlier this ...

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Agomab Ther­a­peu­tics is ben­e­fit­ing from Sanofi’s push to be­come an im­munol­o­gy pow­er­house.

(Reuters) - French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season.

Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks Consensus Estimate of $1.35 per share. Earnings of €2.86 per share rose 12.2 ...